The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Glucocorticoid corticosteroids for Duchenne muscular dystrophy
Abstract
Background Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy of childhood. This incurable disease is characterised by muscle wasting and loss of walking ability leading to complete wheelchair dependence by 13 years of age. Prolongation of walking is one of the major aims of treatment. Objectives The aim of this review was to assess whether glucocorticoid corticosteroids stabilize or improve muscle strength and walking in boys with DMD. Search methods This is an update of the Cochrane systematic review first published in 2004 (Manzur 2004). We searched the Cochrane Neuromuscular Disease Group Trials Register (August 2006) using the term 'Duchenne muscular dystrophy'. We also searched MEDLINE (January 1966 to July 2007), EMBASE (January 1980 to August 2006), CINAHL and LILACS (January 1982 to August 2006). We wrote to authors of published studies and other experts in this disease to help identify other trials, checked the references in the identified trials and hand searched the abstracts of relevant journals. Selection criteria Types of studies: randomised or quasi‐randomised trials. Types of participants: all patients with a definite diagnosis of Duchenne muscular dystrophy. Types of interventions: glucocorticoids such as prednisone, prednisolone, deflazacort or others, with a minimum treatment period of three months. Primary outcome measure: prolongation of walking (independent walking without long leg calipers). Secondary outcome measures: strength outcome measures, manual muscle strength testing using Medical Research Council strength scores, functional outcome measures and adverse events. Data collection and analysis We identified six randomised controlled trials that met the inclusion criteria for our review, and one of these (Beenakker 2005) is a new addition to this update, as it was published subsequent to our first review (Manzur 2004). Two review authors independently selected the trials for the review and assessed methodological quality. Data extraction and inputting were double‐checked. Main results Primary outcome measure: data from one small study used prolongation of walking as an outcome measure and did not show significant benefit. Secondary outcome measures: The meta‐analysis of the results from four randomised controlled trials with altogether 249 participants showed that glucocorticoid corticosteroids improved muscle strength and function over six months. Improvements were seen in time taken to rise from the floor (Gowers' time), nine metres walking time, four‐stair climbing time, ability to lift weights, leg function grade and forced vital capacity. One randomised controlled trial with altogether 28 participants showed that glucocorticoid corticosteroids stabilize muscle strength and function for up to two years. The most effective prednisolone regime appears to be 0.75 mg/kg/day, given in a daily dose regime. Not enough data were available to compare efficacy of prednisone with deflazacort. Adverse effects: Excessive weight gain, behavioural abnormalities, cushingoid appearance and excessive hair growth were all more common with glucocorticoid corticosteroids than placebo. Long‐term adverse effects of glucocorticoid therapy could not be evaluated because of the short‐term duration of the randomised studies. Non‐randomised studies: A number of non‐randomised studies with important efficacy and adverse effects data are tabulated and discussed. Authors' conclusions There is evidence from randomised controlled studies that glucocorticoid corticosteroid therapy in Duchenne muscular dystrophy improves muscle strength and function in the short‐term (six months to two years). The most effective prednisolone regime appears to be 0.75 mg/kg/day, given daily. In the short term, adverse effects were significantly more common but not clinically severe. Long‐term benefits and hazards of glucocorticoid treatment cannot be evaluated from the currently published randomised studies. Non‐randomised studies support the conclusions of functional benefits but also identify clinically significant adverse effects of long‐term treatment. These benefits and adverse effects have implications for future research studies and clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Dystrophin protects the sarcolemma from stresses developed during muscle contraction
Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M., & Sweeney, H. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3710 · Cited by 1,526
Population frequencies of inherited neuromuscular diseases—A world survey
Emery, A. E. H. (1991) · Neuromuscular Disorders · doi:10.1016/0960-8966(91)90039-u · Cited by 1,448
Koenig, M., Beggs, A. H., Moyer, M., Scherpf, S., Heindrich, K., Bettecken, T., Meng, G., Müller, C. R., Lindlöf, M., Kääriäinen, H. A., et al. (1989) · Europe PMC (PubMed Central) · Cited by 1,113
Eagle, M., Baudouin, S. V., Chandler, C., Giddings, D. R., Bullock, R., & Bushby, K. (2002) · Neuromuscular Disorders · doi:10.1016/s0960-8966(02)00140-2 · Cited by 1,009
Arahata, K., & Engel, A. G. (1984) · Annals of Neurology · doi:10.1002/ana.410160206 · Cited by 630
Clinical trial in duchenne dystrophy. I. The design of the protocol
Brooke, M. H., Griggs, R. C., Mendell, J. R., Fenichel, G. M., Shumate, J. B., & Pellegrino, R. J. (1981) · Muscle & Nerve · doi:10.1002/mus.880040304 · Cited by 564
Glucocorticoid corticosteroids for Duchenne muscular dystrophy
Manzur, A., Kuntzer, T., Pike, M., & Swan, A. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003725.pub2 · Cited by 539
Self-citationRandomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular Dystrophy
Mendell, J. R., Moxley, R. T., Griggs, R. C., Brooke, M. H., Fenichel, G. M., Miller, J. P., King, W., Signore, L., Pandya, S., Florence, J., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906153202405 · Cited by 520
Cited by
Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., Kaul, A., Kinnett, K., McDonald, C., Pandya, S., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70271-6 · Cited by 2,053
Evidence-based path to newborn screening for Duchenne muscular dystrophy
Mendell, J. R., Shilling, C., Leslie, N. D., Flanigan, K. M., al‐Dahhak, R., Gastier‐Foster, J., Kneile, K., Dunn, D. M., Duval, B., Aoyagi, A., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23528 · Cited by 813
Satellite Cells and Skeletal Muscle Regeneration
Dumont, N. A., Bentzinger, C. F., Sincennes, M., & Rudnicki, M. A. (2015) · Comprehensive Physiology · doi:10.1002/cphy.c140068 · Cited by 719
McDonald, C. M., Campbell, C., Torricelli, R. E., Finkel, R. S., Flanigan, K. M., Goemans, N., Heydemann, P., Kaminska, A., Kirschner, J., Muntoni, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31611-2 · Cited by 452
Mercuri, E., & Muntoni, F. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61897-2 · Cited by 434
Cellular dynamics in the muscle satellite cell niche
Bentzinger, C. F., Wang, Y. X., Dumont, N. A., & Rudnicki, M. A. (2013) · The EMBO Reports · doi:10.1038/embor.2013.182 · Cited by 398
Hull, J., Aniapravan, R., Chan, E., Chatwin, M., Forton, J., Gallagher, J., Gibson, N., Gordon, J., Hughes, I., McCulloch, R., et al. (2012) · Thorax · doi:10.1136/thoraxjnl-2012-201964 · Cited by 394
Dystrophin-Deficient Cardiomyopathy
Kamdar, F., & Garry, D. J. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.081 · Cited by 384
Skeletal muscle regeneration is modulated by inflammation
Yang, W., & Hu, P. (2018) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2018.01.002 · Cited by 338
Contemporary Cardiac Issues in Duchenne Muscular Dystrophy
McNally, E. M., Kaltman, J. R., Benson, D. W., Canter, C. E., Cripe, L. H., Duan, D., Finder, J. D., Groh, W. J., Hoffman, E. P., Judge, D. P., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.015151 · Cited by 326
Duchenne and Becker Muscular Dystrophies
Flanigan, K. M. (2014) · Neurologic Clinics · doi:10.1016/j.ncl.2014.05.002 · Cited by 317
Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy
Hathout, Y., Brody, E., Clemens, P. R., Cripe, L., DeLisle, R. K., Furlong, P., Gordish-Dressman, H., Hache, L., Henricson, E., Hoffman, E. P., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1507719112 · Cited by 290
Prevalence of Duchenne and Becker Muscular Dystrophies in the United States
Romitti, P. A., Zhu, Y., Puzhankara, S., James, K. A., Nabukera, S. K., Zamba, G. K. D., Ciafaloni, E., Cunniff, C., Druschel, C. M., Mathews, K. D., et al. (2015) · Pediatrics · doi:10.1542/peds.2014-2044 · Cited by 290
Autophagy as a new therapeutic target in Duchenne muscular dystrophy
De Palma, C., Morisi, F., Cheli, S., Pambianco, S., Cappello, V, Vezzoli, M., Rovere-Querini, P., Moggio, M., Ripolone, M., Francolini, M., et al. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.159 · Cited by 269
Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy
Villalta, S. A., Rosenthal, W., Martinez, L., Kaur, A., Sparwasser, T., Tidball, J. G., Margeta, M., Spencer, M. J., & Bluestone, J. A. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009925 · Cited by 254
Creatine for treating muscle disorders
Kley, R. A., Tarnopolsky, M. A., & Vorgerd, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004760.pub4 · Cited by 169
Skeletal Muscle Degenerative Diseases and Strategies for Therapeutic Muscle Repair
Tabebordbar, M., Wang, E. T., & Wagers, A. J. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132450 · Cited by 79
AdipoRon, a new therapeutic prospect for Duchenne muscular dystrophy
Abou‐Samra, M., Selvais, C. M., Boursereau, R., Lecompte, S., Noel, L., & Brichard, S. M. (2020) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12531 · Cited by 44
Lecompte, S., Abou-Samra, M., Boursereau, R., Noel, L., & Brichard, S. M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2465-5 · Cited by 34
Messina, S., Bitto, A., Aguennouz, M., Vita, G. L., Polito, F., Irrera, N., Altavilla, D., Marini, H., Migliorato, A., Squadrito, F., et al. (2011) · Neuromuscular Disorders · doi:10.1016/j.nmd.2011.04.014 · Cited by 33
Potential Therapeutic Action of Adiponectin in Duchenne Muscular Dystrophy
Abou-Samra, M., Boursereau, R., Lecompte, S., Noel, L., & Brichard, S. M. (2017) · The American Journal of Pathology · doi:10.1016/j.ajpath.2017.02.018 · Cited by 24
Metadata
- Authors
- Manzur, A. Y., Kuntzer, T., Pike, M., & Swan, A. V.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2008-01-23
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W4238163958
- Cited by
- 437
- References
- 103
- Type
- reference entry
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.